Maintenance therapy with subcutaneous imsidolimab allowed all treated patients to remain flare-free throughout the GEMINI-2 study period.

Phentolamine ophthalmic solution 0.75% shows significant near vision improvement in patients with presbyopia during the phase 3 VEGA-3 clinical trial.

Most frequent visits among non-mental health conditions addressed by telehealth were for diabetes, HTN, COVID-19 ...

HealthDay News — US health officials are proposing a new way to develop and approve custom-made treatments for people with rare and hard-to-treat conditions.

HealthDay News — A considerable proportion of pregnant women are colonized with enterobacterales with ampicillin (AmpR-E) and ceftriaxone resistance (CefR-E) in the United States, according to a study ...

HealthDay News — A new model can predict when someone is likely to develop symptoms of Alzheimer disease (AD) using a single blood test, according to a study published online February 19 in Nature ...

On Monday, the CDC announced that Ralph Abraham, its deputy secretary general, stepped down effective immediately. Abraham had been in the role for about 2 and a half months. In a statement posted on ...

Pegzilarginase is an enzyme replacement therapy that provides an exogenous source of the deficient human arginase 1 enzyme to reduce blood arginine levels.

Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.

Phase 3 results support QTORIN rapamycin as a potential first targeted therapy for patients with debilitating microcystic lymphatic malformations.

In the phase 2/3 MUSCLE trial, ulviprubart failed to reach statistical significance for functional and strength endpoints in inclusion body myositis.

Clinical guideline developed by the American Heart Association and the American College of Cardiology.